World's Best Scientists 2026 revealed!
Andrea Ardizzoni

Andrea Ardizzoni

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 78 18002 16922 729 697 769 23450

Andrea Ardizzoni publications per year

The chart shows the history of publications by Andrea Ardizzoni between 1984 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Andrea Ardizzoni published across 42 years, from 1984 to 2025, averaging 18.8 papers a year. Output peaked at 66 publications in 2021. 49 of the 791 publications appeared in the last two years.

No. of publications
20 40 60
Bar chart. Horizontal axis: year, 1984 to 2025. Vertical axis: number of publications, 0 to 66. Peak 66 publications in 2021. 1984: 2 publications 1985: 5 publications 1986: 10 publications 1987: 8 publications 1988: 7 publications 1989: 4 publications 1990: 6 publications 1991: 9 publications 1992: 1 publication 1993: 7 publications 1994: 12 publications 1995: 6 publications 1996: 6 publications 1997: 21 publications 1998: 5 publications 1999: 11 publications 2000: 9 publications 2001: 8 publications 2002: 7 publications 2003: 14 publications 2004: 12 publications 2005: 20 publications 2006: 9 publications 2007: 21 publications 2008: 11 publications 2009: 19 publications 2010: 14 publications 2011: 30 publications 2012: 26 publications 2013: 22 publications 2014: 19 publications 2015: 30 publications 2016: 36 publications 2017: 46 publications 2018: 44 publications 2019: 40 publications 2020: 44 publications 2021: 66 publications 2022: 35 publications 2023: 40 publications 2024: 18 publications 2025: 31 publications
1984 2025

791 publications in total across all disciplines

View publications per year as a table
Andrea Ardizzoni: publications per year, 1984 to 2025
Year Publications
1984 2
1985 5
1986 10
1987 8
1988 7
1989 4
1990 6
1991 9
1992 1
1993 7
1994 12
1995 6
1996 6
1997 21
1998 5
1999 11
2000 9
2001 8
2002 7
2003 14
2004 12
2005 20
2006 9
2007 21
2008 11
2009 19
2010 14
2011 30
2012 26
2013 22
2014 19
2015 30
2016 36
2017 46
2018 44
2019 40
2020 44
2021 66
2022 35
2023 40
2024 18
2025 31
Total 791
Download as CSV

Andrea Ardizzoni publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andrea Ardizzoni sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 761–780 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 769 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228 769
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Andrea Ardizzoni D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andrea Ardizzoni sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 78–79 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891 78
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Andrea Ardizzoni is affiliated with the University of Bologna in Italy and focuses primarily on research within the field of Medicine, with a particular emphasis on Oncology. Their work extensively covers subfields such as Pulmonary and Respiratory Medicine, Epidemiology, Molecular Biology, and Surgery.

The scientist has contributed significantly to several main research topics, including:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Diagnosis and Treatment
  • Peptidase Inhibition and Analysis
  • Neuroendocrine Tumor Research Advances

Their publication record shows multiple papers in prominent journals. Among the most recent notable papers are:

  • "Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", 2021, Annals of Oncology
  • "First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC", 2023, New England Journal of Medicine
  • "Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial", 2020, ESMO Open
  • "ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data", 2020, Lung Cancer
  • "CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations", 2020, European Journal of Cancer

The frequent co-authors associated with Andrea Ardizzoni include:

  • Francesco Gelsomino
  • Alessandro Di Federico
  • Andrea De Giglio
  • Francesca Sperandi
  • Filippo Gustavo Dall'Olio

The majority of their work has been published in key academic venues such as:

  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Cancers
  • Journal of Clinical Oncology
  • European Journal of Cancer

Overall, Andrea Ardizzoni's research contributions focus on advancing understanding and treatment methodologies in oncology, with a strong concentration on lung and colorectal cancer studies, immunotherapy, and clinical outcomes related to cancer treatments.

Best Publications

  • Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

    Antonino Musolino;Nadia Naldi;Beatrice Bortesi;Debora Pezzuolo

  • JC‐1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess ΔΨ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis

    Stefano Salvioli;Andrea Ardizzoni;Claudio Franceschi;Andrea Cossarizza

  • Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

    Andrea Ardizzoni;Luca Boni;Marcello Tiseo;Frank V. Fossella

  • Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

    Andrea Ardizzoni;Heine Hansen;Per Dombernowsky;Teresa Gamucci

  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  • Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

    Jean Charles Soria;Enriqueta Felip;Manuel Cobo;Shun Lu

  • Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer

    U Gatzemeier;G Groth;C Butts;N Van Zandwijk

  • Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

    R. Rosell;U. Gatzemeier;D. C. Betticher;U. Keppler

  • Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.

    John R. Eckardt;Joachim von Pawel;Jean-Louis Pujol;Zsolt Papai

  • Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

    A.-M.C. Dingemans;M. Früh;A. Ardizzoni;B. Besse

  • Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel

    Cesare Gridelli;Matti Aapro;Andrea Ardizzoni;Lodovico Balducci

  • Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

    G. Giaccone;A. Ardizzoni;A. Kirkpatrick;M. Clerico

  • Grading the neuroendocrine tumors of the lung: an evidence-based proposal

    G Rindi;C Klersy;F Inzani;G Fellegara

  • Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.

    Giulia Mazzaschi;Denise Madeddu;Angela Falco;Giovanni Bocchialini

  • Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: Results of an European Experts Panel

    C. Gridelli;A. Ardizzoni;T. Le Chevalier;C. Manegold

  • ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 Mg or 600 Mg, Taken With a Low-Fat Meal Versus 750 Mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Byoung Chul Cho;Dong Wan Kim;Alessandra Bearz;Scott A. Laurie

  • Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

    C Bozzetti;F V Negri;C A Lagrasta;P Crafa

  • Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

    Lucia Del Mastro;Sabino De Placido;Paolo Bruzzi;Michele De Laurentiis

  • Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

    Antonino Musolino;Laura Ciccolallo;Michele Panebianco;Elisa Fontana

  • Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

    Jean-Charles Soria;Soria Jean-Charles;Enriqueta Felip;Felip Enriqueta

Frequent Co-Authors

Pierfranco Conte
Pierfranco Conte University of Padua
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Filippo De Marinis
Filippo De Marinis European Institute of Oncology
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Pieter E. Postmus
Pieter E. Postmus Leiden University Medical Center
Paolo Bruzzi
Paolo Bruzzi Ospedale San Martino
Byoung Chul Cho
Byoung Chul Cho Yonsei University
Guido Rindi
Guido Rindi Catholic University of the Sacred Heart
Shirish M. Gadgeel
Shirish M. Gadgeel University of Michigan–Ann Arbor
Federico Cappuzzo
Federico Cappuzzo Azienda Unità Sanitaria Locale Della Romagna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in Medicine opens up diverse educational and career options beyond the traditional MD route. Many students start their healthcare careers with lpn online programs, which offer flexible, accessible training for those seeking to enter the field quickly. These programs can serve as stepping stones to advanced nursing roles or further medical study.

For those interested in mental health, pursuing the shortest pmhnp program online can lead to a career as a Psychiatric Mental Health Nurse Practitioner. This path allows students to complete their education faster and begin addressing critical mental health needs in their communities sooner.

Alternatively, if you’re drawn to the management side of healthcare, consider health administration degrees online. These programs blend healthcare knowledge with business and leadership skills, preparing graduates for important non-clinical roles in hospitals and healthcare organizations.

Those looking to advance further may pursue a master’s degree. The masters in healthcare administration cost can vary widely, but affordable online options make this advanced credential more accessible than ever. With the right program, you can build a rewarding career while managing tuition costs responsibly.

Best Scientists Citing Andrea Ardizzoni

Trending Scientists

Recently Published Articles